Skip to main content

Branded

  • FDA approves Flublok Quadrivalent flu vaccine

    FDA approves Flublok Quadrivalent flu vaccine
     
    SILVER SPRING, Md. — The Food and Drug Administration has approved Protein Sciences’s Flublok Quadrivalent flu vaccine, the company announced Wednesday. The vaccine protects against four strains of influenza, three of which are found in trivalent Flublok alongside a fourth strain. 
     

  • HDA Research Foundation names new COO

    ARLINGTON, Va. – The HDA Research Foundation (formerly the Center for Healthcare Supply Chain Research) on Thursday named Perry Fri its new COO. He assumes leadership of the Foundation, the 501(c)(3) non-profit charitable organization of the Healthcare Distribution Alliance (HDA, formerly HDMA), from Karen Ribler, who retired at the end of September.

  • Lupin, MonoSol Rx ink licensing agreement for pediatric products

    WARREN, New Jersey, BALTIMORE and MUMBAI — Lupin on Tuesday announced a new strategic licensing agreement with specialty pharmaceutical company MonoSol Rx. Under the agreement, Lupin would develop multiple pediatric products using Monosol Rx’s PharmFilm drug delivery technology. 
     

  • FDA approves Orexo’s low-dose Zubsolv

    SILVER SPRING, Md. — The Food and Drug Administration has approved Orexo’s Zubsolv (buprenorphine 0.7 mg/naloxone 0.18 mg) sublingual tablets, the company announced Thursday. The drug is indicated to treat patients with opioid dependence. 
     
    With this approval, Orexo now has FDA approval for six dosage strength tablets: 11.4 mg buprenorphine/2.9 mg naloxone, 8.6 mg/2.1 mg, 5.7 mg/1.5 mg, 2.9 mg/0.71 mg, 1.4 mg/0.36 mg and 0.7 mg/0.18 mg. 
     

  • Jean Coutu Group launches flu shot awareness campaign

    VARENNES, Quebec - The Jean Coutu Group on Tuesday launched a flu shot awareness campaign under the theme "Protect Your Health and That of Your Loved Ones." The campaign aims to support the public health effort for flu prevention by making the flu shot available in more than 300 stores in the Jean Coutu network throughout Quebec, in Ontario and New Brunswick.

  • Health Canada approves Adapt Pharma’s Narcan Nasal Spray

    DUBLIN, Ireland — Health Canada on Tuesday approved naloxone hydrochloride nasal spray, a nasal delivery method for the opioid overdose medication, which Adapt Pharma said it would market as Narcan Nasal Spray. 
     

  • Eisai, Arena announce availability of Belviq XR

    WOODCLIFF LAKE, N.J. — Eisai and Arena Pharmaceuticals have announced the availability of Belviq XR (lorcaserin HCl) extended-release tablets. The new formulation offers a once-daily dosing option that the company says may help some patients achieve and maintain weight loss. 
     

  • Prime Therapeutics finds increase in long-acting opioid claims

    ST. PAUL, Minn. — Pharmacy benefit manager Prime Therapeutics recently analyzed pharmacy claims for short- and long-acting opioids, finding a decrease in short-acting opioid claims and an increase in long-acting opioid claims. The review of 15 million commercially insured members found an overall 3.9% decrease in opioid claims from 2014 to 2015. 
     
X
This ad will auto-close in 10 seconds